Clinical study on combination of homoharringtonine, Ara-C and idarubicin induction for treatment of newly diagnosed acute myeloid leukemia patients.
- Author:
Tie-Jun QIN
1
;
Ze-Feng XU
;
Li-Wei FANG
;
Hong-Li ZHANG
;
Yue ZHANG
;
Jing-Zhe WANG
;
Li-Juan PAN
;
Nai-Bo HU
;
Zhi-Jian XIAO
Author Information
1. Chinese Academy of Medical Sciences, Tianjin, China.
- Publication Type:Clinical Trial
- MeSH:
Adolescent;
Adult;
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Cytarabine;
administration & dosage;
therapeutic use;
Female;
Harringtonines;
administration & dosage;
therapeutic use;
Humans;
Idarubicin;
administration & dosage;
therapeutic use;
Induction Chemotherapy;
Leukemia, Myeloid, Acute;
drug therapy;
Male;
Middle Aged;
Young Adult
- From:
Journal of Experimental Hematology
2011;19(5):1277-1282
- CountryChina
- Language:Chinese
-
Abstract:
The purpose of this study was to assess the efficacy and toxicity of HAI regimen [(homoharringtonine 2.5 mg/(m(2)×d), days 1 - 7; cytarabine 150 mg/(m(2)×d), days 1 - 7; idarubicin 9 mg/(m(2)×d), days 1 - 7)] for induction treatment of newly diagnosed acute myeloid leukemia (AML) (except acute promyelocytic leukemia). 31 patients with newly diagnosed AML, aged 39 (14 - 58) years, were enrolled in this clinical study. The complete remission (CR) rate, especially after one course, the overall survival (OS) rate and relapse free survival (RFS) rate were estimated. The outcomes were compared between different prognostic groups according to World Health Organization (WHO) classification, genetics and initial WBC count. Safety was evaluated using standard WHO criteria. The results showed that 26 patients (84%) achieved CR after 1 course of induction. The CR rate for the patients with favorable, intermediate and unfavorable cytogenetics was 90%, 88% and 60% respectively. All 7 patients with a high initial WBC count (≥ 100×10(9)/L) obtained CR, while 19 out of 24 without a high initial WBC count obtained CR. With a median follow-up of 15(range 2-56) months, the estimated 3-year OS rate for all patients and the patients with CR was 44% and 52% respectively. The 3-year RFS rate was 51%. The patients receiving induction chemotherapy died of the chemotherapy. Profound myelosuppression was seen in all patients after the HAI induction with the median duration of neutropenia (ANC < 0.2×10(9)/L) of 16 (6 - 24) days. As the most common toxicity, severe infections (grade III-IV) involved in all the patients and the duration of febris was 6 (1 - 36) days. The incidence of septemia and invasive fungus infection were 19.4% and 45.2% respectively. The incidence of non-infection fever, increased glutamic-pyruvic transaminase (GPT), diarrhea, increased bilirubin and oral cavity mucositis were 6.5%, 6.5%, 3.2%, 3.2%, 3.2% respectively, as the more frequent severe non-hematological toxicities. It is concluded that HAI regimen is a high efficient induction schedule for the newly diagnosed AML, and archive the higher CR rate after one course than DNR/Ara-C standard induction regimen. Side effects are acceptable, except severe infection.
